Ignite Creation Date:
2024-05-06 @ 2:47 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04427072
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2020-06-09
Brief Title:
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Carcinoma Non-Small-Cell Lung |
Keywords:
| Name | View |
|---|---|
| docetaxel | View |
| Non small cell lung cancer | View |
| Non small cell lung carcinoma | View |
| NSCLC | View |
| INC280 | View |
| capmatinib | View |
| MET mutation | View |
| MET exon14 | View |
| MET exon14 skipping | View |
| MET exon14 deletion | View |
| METex14 | View |
| METex14del | View |
| METex14 | View |
| EGFRwt | View |
| Epidermal growth factor receptor wild type | View |
| ALK negative | View |